RxDoctor Payments Data

Laurie Grossberg, MD

Gastroenterology · Boston, MANPI 1699069252

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Pfizer at 49.2% of the total. Reporting peaked in 2024 at $7,233 and has fallen 69.0% since, to $2,244 in 2025.

$14,712in general payments, 2019–2025

Across 12 payments — averaging $1226.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Johnson & Johnson$2K
  • Bristol Myers Squibb$160
$347,629in research payments, 2019–2025

Across 42 payments — averaging $8276.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$150K
  • Janssen Research & Development, LLC$82K
  • AbbVie$42K
  • Eli Lilly$31K
  • Pfizer$27K
  • E.r. Squibb & Sons, L.L.C.$15K

What the payments were for

  • Consulting fees$7,17549%
  • Speaking & faculty fees$5,70039%
  • Travel & lodging$1,3029%
  • Food & beverage$5053%
  • Education$300%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer5$7,233
E.r. Squibb & Sons, L.L.C.1$5,075
Johnson & Johnson2$2,244
Bristol Myers Squibb4$160

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,712 in reported general payments places this provider in the 85th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$26,999
Medicare patients
100
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab43$1,103,691
Humira(Cf) PenAdalimumab31$356,073
Humira PenAdalimumab13$174,267
RinvoqUpadacitinib13$80,217
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates89$6,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$2,244$1,103,69143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →